Pentavalent DTaP-Hep B-IPV

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
DiphtheriaHepatitis BPoliomyelitisPertussisTetanus
Interventions
BIOLOGICAL

DTaP-Hep B-IPV Vaccine

U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.

BIOLOGICAL

Monovalent Hep B Vaccine

U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.

DRUG

Placebo

Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.

Trial Locations (1)

90502

UCLA Center For Vaccine Research, Torrance

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00133445 - Pentavalent DTaP-Hep B-IPV | Biotech Hunter | Biotech Hunter